Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | TPO | P07202 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4363951 | 0.80 | MTOR (0.47) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL8043932 | 0.77 | ADRA2A (0.49) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL9287236 | 0.75 | NISCH (0.64) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL8667511 | 0.74 | CSNK1A1 (0.50) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL14886257 | 0.73 | NISCH (0.61) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL4633326 | 0.73 | RAB9A (0.56) | ALDH1A1KDM4E | |
| SCHEMBL8687630 | 0.72 | CSNK1A1 (0.42) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL5479162 | 0.71 | HTR2A (0.49) | ADRA2AALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3278270 | 0.71 | MTOR (0.46) | CSNK1A1TYRO3DYRK1BNISCHMTOR | |
| SCHEMBL6509762 | 0.71 | CSNK1A1 (0.57) | CSNK1A1TYRO3DYRK1BNISCHMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101583615-B | Spiropiperidine glycinamide derivatives | HOFFMANN LA ROCHE | 2012-07-04 | — | — | CN | disclosed |
| EP-2104677-B1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-12-07 | — | — | EP | disclosed |
| CN-101583615-A | Spiropiperidine glycinamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-11-18 | — | — | CN | disclosed |
| EP-2104677-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498339-B2 | Spiropiperidine glycinamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008084005-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE, INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194610-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | CSNK1A1 723/4885TYRO3 2681/4885DYRK1B 1742/4885 |
| US-20080171760-A1 | e.g. N-[(4-Chlorophenyl)(phenyl)methyl]-2-oxo-2-(1'H,3H-spiro[2-indane-1,4'-piperidin]-1'-yl)ethanamine; vasopressin V1a receptor antagonist; antidepressant, anxiolytic, hypotensive agent; dysmenorrhea, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | AVPR1A, AVPR2, AVPR1B | CSNK1A1 749/4885TYRO3 4151/4885DYRK1B 3360/4885 |
| US-20080171759-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | AVPR1A, AVPR1B, GLRA1 | CSNK1A1 723/4885TYRO3 2681/4885DYRK1B 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.